Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5PBLM)

Drug Name

EYP001 Drug Info

Synonyms

Vonafexor; 1192171-69-9; UNII-XG6DG6A1UN; XG6DG6A1UN; 4-chloro-5-[4-(2,6-dichlorobenzene-1-; sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid; Vonafexor [INN]; SCHEMBL1893285; Vonafexor(PLX007,EYP-001); BCP33693; EX-A4037; EYP001;EYP 001;EYP-001; HY-109197; CS-0119143; 2-Benzofurancarboxylic acid, 4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)-1-piperazinyl)-; 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Non-alcoholic steatohepatitis	DB92.1	Phase 2	[1]

Cross-matching ID

PubChem CID: 67202717
CAS Number: CAS 1192171-69-9
TTD Drug ID: DM5PBLM

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Farnesoid X-activated receptor (FXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[3]
Guggulsterone	DMP7LK1	Osteoarthritis	FA00-FA05	Approved	[4]
Obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[5]
Bevacizumab + Trastuzumab	DM9CEI5	Breast cancer	2C60-2C65	Phase 3	[3]
GS-9674	DM936V7	Primary sclerosing cholangitis	DB96.2	Phase 3	[6]
Apomine	DM6B9HP	Osteopetrosis	LD24.10	Phase 2	[7]
LJN452	DM3XRUH	Primary biliary cholangitis	DB96.1	Phase 2	[8]
EDP-305	DMGJYZ8	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[9]
LMB763	DMQOXNL	Diabetic nephropathy	GB61.Z	Phase 2	[10]
MET409	DM89QXT	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03812029) Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of ENYO Pharma.
3	Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
4	Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
5	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
6	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
7	The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
8	FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
9	A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
10	Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
11	Clinical pipeline report, company report or official report of Metacrine.